Somatropin

Why Researchers Study Somatropin

Somatropin is recombinant human growth hormone (rHGH) — a 191-amino-acid polypeptide identical in sequence to endogenous pituitary GH, produced via rDNA expression. It is the reference compound for growth-hormone research, used to study the GH/IGF-1 axis, body-composition regulation, tissue repair, and metabolic signalling in controlled models.

Unlike GH secretagogues (which prompt the pituitary to release its own GH in pulses), somatropin delivers the hormone directly, giving researchers precise control over exposure and timing.

Mechanism of Action

Somatropin binds the transmembrane growth-hormone receptor (GHR) on target tissues. Receptor dimerisation activates the associated JAK2 tyrosine kinase, which phosphorylates STAT5; the pathway drives transcription of GH-responsive genes and, in hepatocytes, hepatic secretion of insulin-like growth factor 1 (IGF-1). IGF-1 mediates much of the downstream anabolic and regenerative signalling attributed to GH, while GH itself exerts direct lipolytic and insulin-modulating effects on adipose and muscle tissue.

Research Context

Investigational literature examines somatropin in the context of lean-mass and adipose-tissue regulation, connective-tissue and wound-repair models, bone-turnover markers, and IGF-1 dose-response. Its well-characterised pharmacology makes it a common positive control when benchmarking novel secretagogues and GHRH analogs.

Handling & Reconstitution

Supplied as a lyophilised powder. Reconstitute with bacteriostatic water, added slowly against the vial wall (never injected directly onto the pellet), and swirl gently rather than shake — HGH is a fragile protein and vigorous agitation can denature it. Store lyophilised vials refrigerated; keep reconstituted solution at 2–8 °C and protected from light.